{ "items": [ "\n\n
\n \n\n \n \n \n \n MORU\n \n \n \n \n NDM-CGHR\n \n \n\n \n\n\n
\n \n\n \n5 August 2020
\n \n \n \nBlog by Professor Christiane Dolecek. Antimicrobial resistance is a critical problem in enteric fever. Drug-resistant infections can have severe consequences, and slowing their spread requires our urgent attention. The most important intervention is to reduce the number of infections; vaccines are a critical tool, alongside surveillance and diagnosis. To achieve this control, strong partnerships between WHO, governments, NGOs, academia, private sector and communities are needed.
\n \n\n \n \n\n \n\n \n \n \n \n MORU\n \n \n\n \n\n\n
\n \n\n \n30 June 2020
\n \n \n \nThe UK regulator MHRA announced on 26 June that it would again permit recruitment to the COPCOV COVID-19 prevention clinical trial. The MHRA decision came 5 weeks after it reacted immediately to the now-discredited paper published in The Lancet suggesting harms with hydroxychloroquine, and paused recruitment of UK participants. But The Lancet paper was based on fabricated data and was swiftly retracted. After this interruption, recruitment around the globe to COPCOV can now resume.
\n \n\n \n \n\n \n\n \n \n \n \n General\n \n \n \n \n MORU\n \n \n\n \n\n\n
\n \n\n \n9 June 2020
\n \n \n \nOn 4 June 2020, after a week of increasing scientific concern and scrutiny, first The Lancet, then the New England Journal of Medicine, retracted studies that were based on inaccessible data. The studies have been extremely damaging to chloroquine and hydroxychloroquine COVID-19 clinical trials around the globe. MORU researchers played a key role in bringing this scandal to light, whose consequences continue to play out.
\n \n\n \n \n\n \n\n \n \n \n \n General\n \n \n \n \n MORU\n \n \n\n \n\n\n
\n \n\n \n5 June 2020
\n \n \n \nOn 4 June 2020, after a week of increasing scientific concern and scrutiny, first The Lancet, then a little over an hour later the New England Journal of Medicine, retracted studies that were based on inaccessible data, provided by the Surgisphere corporation. The studies have been extremely damaging to chloroquine and hydroxychloroquine COVID-19 clinical trials around the globe. Here is MORU\u2019s statement in response to these events.
\n \n\n \n \n\n \n\n \n \n \n \n MORU\n \n \n\n \n\n\n
\n \n\n \n21 May 2020
\n \n \n \nA global study to test if either chloroquine or hydroxychloroquine can prevent COVID-19 in vital frontline healthcare workers will open to UK participants at hospital sites in Brighton and Oxford today.
\n \n\n \n \n\n \n\n \n \n \n \n MORU\n \n \n\n \n\n\n
\n \n\n \n1 May 2020
\n \n \n \nThe SEBCOV study aims to produce evidence to inform public health measures such as communications, quarantine, self-isolation, social distancing and travel restrictions for the COVID-19 pandemic. This study is run in four countries: UK, Thailand, Italy and Malaysia.
\n \n\n \n \n\n \n\n \n \n \n \n MORU\n \n \n\n \n\n\n
\n \n\n \n29 April 2020
\n \n \n \nThe Epidemiology Department of MORU and National Malaria Control Programme, Cambodia (CNM) have begun to implement a study to assess the efficacy of prophylaxis with artemether-lumefantrine (PAL) against forest malaria in Siem Pang District, north-eastern Cambodia bordering Laos.
\n \n\n \n \n\n \n\n \n \n \n \n MORU\n \n \n\n \n\n\n
\n \n\n \n24 April 2020
\n \n \n \nThe impact of COVID-19 is quite evident at present \u2013 entire countries and cities are under lockdown, offices and industries shut and academia at a standstill. However, many people in Bangladesh remain unaware or indifferent to the warnings and safety protocols that ought to be followed to stop COVID-19\u2019s spread. Since enforcing social distancing in a densely populated country like Bangladesh is very challenging, making people aware and maintenance of hygiene are the main means to stop the spread of COVID-19.
\n \n\n \n \n\n \n\n \n \n \n \n COMRU\n \n \n \n \n LOMWRU\n \n \n \n \n MORU\n \n \n\n \n\n\n
\n \n\n \n23 April 2020
\n \n \n \nLess than a month after it was announced, the MORU-led COPCOV study has made quick progress and expects to begin enrolling participants by the end of April.
\n \n\n \n \n\n \n\n \n \n \n \n MORU\n \n \n \n \n NDM-CGHR\n \n \n\n \n\n\n
\n \n\n \n10 April 2020
\n \n \n \nGlobal health experts have united in a call for governments and international organisations around the world to plan strategically for the coordinated production, equitable distribution and surveillance of COVID-19 medical products to ensure access to quality-assured medications for everyone.
\n \n\n \n \n\n \n\n \n \n \n \n MORU\n \n \n \n \n Video\n \n \n\n \n\n\n
\n \n\n \n6 April 2020
\n \n \n \nThere are currently no proven vaccines or drugs to prevent COVID-19. In this BBC World News interview, MORU\u2019s Prof Sir Nick White explains why the only way to find out if chloroquine and hydroxychloriquine work against COVID-19 is via randomised, clinical trials and how the hype over chloroquine negatively affects people with lupus and rheumatoid arthritis.
\n \n\n \n \n\n \n\n \n \n \n \n MORU\n \n \n\n \n\n\n
\n \n\n \n30 March 2020
\n \n \n \nResearchers at MORU and two institutions in the US (University of Washington and La Jolla Institute for Immunology) receive grants from the COVID-19 Therapeutics Accelerator, a large-scale initiative launched by the Bill & Melinda Gates Foundation, Wellcome, and Mastercard to speed the development of and access to therapies for COVID-19.
\n \n\n \n \n\n \n\n \n \n \n \n MORU\n \n \n \n \n NDM-CGHR\n \n \n\n \n\n\n
\n \n\n \n30 March 2020
\n \n \n \nThe problem of substandard and falsified (SF) medical products affects all countries but few regulatory authorities or pharmaceutical companies have policies of publicly releasing data. As a first step in tracking this global issue, IDDO\u2019s Medicine Quality Research Group, with the MORU Tropical Health Network and supported by a grant from the Wellcome Trust, has today launched a new, free-to-use, online tool, the Medicine Quality Monitoring Globe, (MQM Globe) which maps SF news reports worldwide in real time.
\n \n\n \n \n\n \n\n \n \n \n \n MORU\n \n \n\n \n\n\n
\n \n\n \n11 March 2020
\n \n \n \nAdding a third anti-malaria drug to current artemisinin-combination therapies (ACTs) provides effective treatment against multidrug-resistant falciparum malaria in Southeast Asia, say Oxford researchers in a study in The Lancet. Using TACTs should extend current malaria drugs so drug-resistant malaria doesn't kill millions more and derail hopes of controlling and eliminating malaria.
\n \n\n \n \n\n \n\n \n \n \n \n MORU\n \n \n \n \n Public Engagement\n \n \n\n \n\n\n
\n \n\n \n10 January 2020
\n \n \n \nWhen we are ill, we expect our medicines to work as intended. But what if they do not contain the ingredients listed on the packaging? The Pharmacide Arts exhibition \u201cWhat\u2019s in your medicines?\u201d showcases the original artwork of 11 South East Asian artists. The exhibition is open to the public from 26th-28th January 2020 at the Mandarin Hotel, Bangkok, from 10 am \u2013 5 pm.
\n \n\n \n \n\n \n\n \n \n \n \n Awards & Appointments\n \n \n \n \n MORU\n \n \n\n \n\n\n
\n \n\n \n22 November 2019
\n \n \n \nProfessor Joel Tarning received a Bailey K. Ashford Medal at the ASTMH 2019 Conference. The medal is awarded annually for distinguished work in tropical medicine by an early- to mid-career ASMTH member. Joel is Head of Clinical Pharmacology at MORU and his work focuses on applying pharmacokinetic-phamacodynamic modelling to optimise antimalarial drug therapies, in particular for at-risk groups such as malnourished children and pregnant women.
\n \n\n \n \n\n \n\n \n \n \n \n MORU\n \n \n \n \n NDM-CGHR\n \n \n\n \n\n\n
\n \n\n \n8 November 2019
\n \n \n \nNoting that substandard and falsified medical products (including medicines, vaccines, biologics, and diagnostics) represent a significant and growing threat to human health, The Lancet Global Health published 'The Global access to quality-assured medical products: the Oxford Statement and call to action'. The Oxford Statement has been signed by 159 attendees at the 2018 Oxford Conference on Medicine Quality and Public Health from governments, multilateral agencies, academia and civil society.
\n \n\n \n \n\n \n\n \n \n \n \n MORU\n \n \n \n \n NDM-CGHR\n \n \n \n \n Public Engagement\n \n \n\n \n\n\n
\n \n\n \n16 October 2019
\n \n \n \nWhen we are ill, we trust that the medicines that we take will make us feel and be better. But what if our pills do not contain the ingredients listed on the packaging? The art exhibition \u2018What\u2019s in your medicines?\u2019 explores how substandard and falsified (\u2018fake\u2019) medicines can affect our health, by showcasing the striking and original artwork of 12 South East Asian artists.
\n \n\n \n \n\n \n\n \n \n \n \n Awards & Appointments\n \n \n \n \n KWTRP\n \n \n \n \n MORU\n \n \n \n \n NDM-CGHR\n \n \n\n \n\n\n
\n \n\n \n9 October 2019
\n \n \n \nOxford Medical Sciences Divisional Panel has conferred the title of Professor on three members of our Centre. Ben Cooper - Professor of Epidemiology, Sassy Molyneux - Professor of Global Health and Piero Olliaro - Professor of Poverty Related Infectious Diseases were awarded these titles in recognition of their distinction in their respective fields and contributions to the research, teaching and administration of the Department and we congratulate them on their success!
\n \n\n \n \n\n \n\n \n \n \n \n MORU\n \n \n\n \n\n\n
\n \n\n \n8 October 2019
\n \n \n \nAn individual patient data meta-analysis of 2,017 patients from 19 studies has found a high risk of recurrence following treatment of P. vivax malaria with artemether-lumefantrine (AL) and dihydroartemisinin-piperaquine (DP) unless they are co-administered with primaquine. The research supports recommendations that these artemisinin-based combination therapies (ACT) should be combined with primaquine.
\n \n\n \n \n